Koyi Hirsh, Hillerdal Gunnar, Andersson Olov, Kölbeck Karl-Gustav, Liv Per, Brandén Eva
Department of Respiratory Medicine, Gävle Hospital, 80187 Gävle, Sweden ; Karolinska Institutet, Stockholm, Sweden ; Centre for Research and Development, Uppsala University, County Council of Gävleborg, Gävle, Sweden.
Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Solna, Stockholm, Sweden.
Lung Cancer Int. 2015;2015:317868. doi: 10.1155/2015/317868. Epub 2015 Jul 14.
An increasing proportion of cancer patients are aged >65 years and many are aged >70 years. Treatment of the elderly with lung cancer has, therefore, become an important issue; so we performed a retrospective study of our patients to demonstrate how elderly patients with NSCLC are treated in real-life, clinical practice. All patients aged ≥70 years with NSCLC at our department were reviewed retrospectively. In total, 1059 patients (50.8% of all NSCLC patients). Of these patients, 243 (22.9%) received chemotherapy, 164 (70.4%) of whom were treated with a platinum doublet using carboplatin. Second- and third-line chemotherapy were given to 31.4% and 13.9% of patients, respectively. Median overall survival was 289 and 320 days for male and female patients, respectively. Patients with performance status (PS) 0 experienced significantly better survival than patients with PS1 or PS 2: 410, 314, and 204 days, respectively. Age was of less importance, with patients aged 70-79 years versus those aged ≥80 years. Treatment of elderly NSCLC patients with chemotherapy is feasible if they have a good PS and appears to prolong survival. In this study, we found no significant differences in survival either between age groups or genders.
年龄大于65岁的癌症患者比例日益增加，许多患者年龄超过70岁。因此，老年肺癌患者的治疗已成为一个重要问题；所以我们对我们的患者进行了一项回顾性研究，以展示非小细胞肺癌老年患者在现实临床实践中的治疗方式。对我们科室所有年龄≥70岁的非小细胞肺癌患者进行回顾性分析。共有1059例患者（占所有非小细胞肺癌患者的50.8%）。在这些患者中，243例（22.9%）接受了化疗，其中164例（70.4%）采用卡铂双药联合铂类化疗。分别有31.4%和13.9%的患者接受了二线和三线化疗。男性和女性患者的中位总生存期分别为289天和320天。体能状态（PS）为0的患者生存期明显优于PS为1或PS为2的患者：分别为410天、314天和204天。年龄的影响较小，70 - 79岁患者与年龄≥80岁患者相比。对于体能状态良好的老年非小细胞肺癌患者，化疗是可行的，且似乎能延长生存期。在本研究中，我们发现年龄组之间或性别之间在生存期方面无显著差异。
